These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34288482)

  • 1. Known and new facts on basal cell carcinoma.
    Seidl-Philipp M; Frischhut N; Höllweger N; Schmuth M; Nguyen VA
    J Dtsch Dermatol Ges; 2021 Jul; 19(7):1021-1041. PubMed ID: 34288482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced basal cell carcinoma: What dermatologists need to know about treatment.
    Wilson M; Johnson RP; Senft SC; Pan EY; Krakowski AC
    J Am Acad Dermatol; 2022 Jun; 86(6S):S14-S24. PubMed ID: 35577406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments on the horizon for locally advanced basal cell carcinoma.
    Idriss MH; Stull CM; Migden MR
    Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current landscape for treatment of advanced basal cell carcinoma.
    Foley P
    Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
    Zargari O; Azimi SZ; Geranmayeh S
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding and managing locally advanced basal cell carcinoma: insights into pathogenesis, therapeutic strategies, and the role of hedgehog pathway inhibitors.
    Cebolla-Verdugo M; Llamas-Segura C; Velasco-Amador JP; Almazán-Fernández FM; Ruiz-Villaverde R
    Ital J Dermatol Venerol; 2024 Oct; 159(5):530-542. PubMed ID: 39422527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying patients at risk for recurrent or advanced BCC.
    Hamid O; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
    Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
    Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal cell carcinoma-treatments for the commonest skin cancer.
    Berking C; Hauschild A; Kölbl O; Mast G; Gutzmer R
    Dtsch Arztebl Int; 2014 May; 111(22):389-95. PubMed ID: 24980564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging trends in the treatment of advanced basal cell carcinoma.
    Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
    Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.